Patient and disease characteristics, and outcome
| Factor . | Age < 60 y (n = 653) . | Age ≥ 60 y (n = 664) . | Overall (n = 1317) . |
|---|---|---|---|
| N (%) . | N (%) . | N (%) . | |
| Age, y | |||
| Mean ± SD | 45.5 ± 11.1 | 69.1 ± 56.0 | 57.4 ± 14.8 |
| Median | 48 | 69 | 60 |
| Range | 17-59 | 60-87 | 17-87 |
| WBC, per mm3 | |||
| Mean ± SD | 11.1 ± 11.9 | 9.3 ± 11.2 | 10.2 ± 11.6 |
| Median | 5.8 | 4.1 | 5.0 |
| Range | 0.4-48.0 | 0.3-48.6 | 0.3-48.6 |
| Etiology | |||
| De novo | 414 (63) | 314 (47) | 728 (55) |
| Secondary | 239 (37) | 350 (53) | 589 (45) |
| Diagnosis to treatment, d | |||
| Mean ± SD | 6.8 ± 10.0 | 7.5 ± 8.7 | 7.2 ± 9.4 |
| Median | 4 | 5 | 4 |
| Range | 1-74 | 1-78 | 1-78 |
| Performance status | |||
| 0 | 96 (15) | 67 (10) | 163 (12) |
| 1 | 365 (56) | 345 (52) | 710 (54) |
| 2 | 76 (12) | 119 (18) | 195 (15) |
| 3-4 | 20 (3) | 34 (5) | 54 (4) |
| Unknown | 96 (15) | 99 (15) | 195 (15) |
| Cytogenetics | |||
| Favorable | 82 (13) | 23 (3) | 105 (8) |
| Intermediate | 425 (65) | 449 (68) | 874 (66) |
| Unfavorable | 146 (22) | 192 (29) | 338 (26) |
| Cytarabine treatment | |||
| Conventional | 113 (17) | 147 (22) | 260 (20) |
| Mid-dose CI | 266 (41) | 224 (34) | 490 (37) |
| Mid- to high-dose bolus | 273 (42) | 289 (44) | 562 (43) |
| Unknown response | 1 (0.1) | 4 (0.6) | 5 (0.4) |
| CR | 439 (67) | 362 (55) | 801 (61) |
| No CR | 214 (33) | 302 (45) | 516 (39) |
| Survival, wk | |||
| No. of failures | 405 (62) | 543 (82) | 948 (72) |
| Median | 68.0 | 33.0 | 48.0 |
| Factor . | Age < 60 y (n = 653) . | Age ≥ 60 y (n = 664) . | Overall (n = 1317) . |
|---|---|---|---|
| N (%) . | N (%) . | N (%) . | |
| Age, y | |||
| Mean ± SD | 45.5 ± 11.1 | 69.1 ± 56.0 | 57.4 ± 14.8 |
| Median | 48 | 69 | 60 |
| Range | 17-59 | 60-87 | 17-87 |
| WBC, per mm3 | |||
| Mean ± SD | 11.1 ± 11.9 | 9.3 ± 11.2 | 10.2 ± 11.6 |
| Median | 5.8 | 4.1 | 5.0 |
| Range | 0.4-48.0 | 0.3-48.6 | 0.3-48.6 |
| Etiology | |||
| De novo | 414 (63) | 314 (47) | 728 (55) |
| Secondary | 239 (37) | 350 (53) | 589 (45) |
| Diagnosis to treatment, d | |||
| Mean ± SD | 6.8 ± 10.0 | 7.5 ± 8.7 | 7.2 ± 9.4 |
| Median | 4 | 5 | 4 |
| Range | 1-74 | 1-78 | 1-78 |
| Performance status | |||
| 0 | 96 (15) | 67 (10) | 163 (12) |
| 1 | 365 (56) | 345 (52) | 710 (54) |
| 2 | 76 (12) | 119 (18) | 195 (15) |
| 3-4 | 20 (3) | 34 (5) | 54 (4) |
| Unknown | 96 (15) | 99 (15) | 195 (15) |
| Cytogenetics | |||
| Favorable | 82 (13) | 23 (3) | 105 (8) |
| Intermediate | 425 (65) | 449 (68) | 874 (66) |
| Unfavorable | 146 (22) | 192 (29) | 338 (26) |
| Cytarabine treatment | |||
| Conventional | 113 (17) | 147 (22) | 260 (20) |
| Mid-dose CI | 266 (41) | 224 (34) | 490 (37) |
| Mid- to high-dose bolus | 273 (42) | 289 (44) | 562 (43) |
| Unknown response | 1 (0.1) | 4 (0.6) | 5 (0.4) |
| CR | 439 (67) | 362 (55) | 801 (61) |
| No CR | 214 (33) | 302 (45) | 516 (39) |
| Survival, wk | |||
| No. of failures | 405 (62) | 543 (82) | 948 (72) |
| Median | 68.0 | 33.0 | 48.0 |